Tacrolimus trough level and oxidative stress in Tunisian kidney transplanted patients
Rattachement africain : Tunisie. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background The effect of tacrolimus (TAC) on oxidative stress after kidney transplantation (KT) is unclear. This study aimed to evaluate the influence of TAC trough levels of oxidative stress status in Tunisian KT patients during the post-transplantation period (PTP).Methods A prospective study including 90 KT patients was performed. TAC whole-blood concentrations were measured by the microparticle enzyme immunoassay method and adjusted according to the target range. Plasma levels of oxidants (malondialdehyde (MDA) and advanced oxidation protein products (AOPP)) and antioxidants (ascorbic acid, glutathione (GSH), glutathione peroxidase (GPx), and superoxide dismutase (SOD)) were measured using spectrophotometry. The subjects were subdivided according to PTP into three groups: patients with early, intermediate, and late PT. According to the TAC level, they were subdivided into LL-TAC, NL-TAC, and HL-TAC groups.Results A decrease in MDA levels, SOD activity, and an increase in GSH levels and GPx activity were observed in patients with late PT compared to those with early and intermediate PT (p < 0.05). Patients with LL-TAC had lower MDA levels and higher GSH levels and GPx activity compared with the NL-TAC and HL-TAC groups (p < 0.05).Conclusion Our results have shown that in KT patients, despite the recovery of kidney function, the TAC reduced but did not normalize oxidative stress levels in long-term therapy, and the TAC effect significantly depends on the concentration used.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Tacrolimus trough level and oxidative stress in Tunisian kidney transplanted patients
- Date Crossref
- 12/02/2024
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Sfax Laboratory of Research of Pharmacology and Toxicology University of Sfax, Tunisie (code pays fourni par la source)Université ou école supérieure
-
Faculty of Sciences of Sfax Faculty of Sciences of Sfax, Tunisie (code pays fourni par la source)Université ou école supérieure
-
Hopital Universitaire Hedi Chaker Tunisie (code pays fourni par la source)Établissement de santé
-
Faculty of Medicine Department of Pharmacology University of Sfax, Tunisie (pays nommé en fin d’affiliation)Université ou école supérieure
-
Hedi Chaker University Hospital Department of Nephrology University of Sfax, Tunisie (pays nommé en fin d’affiliation)Université ou école supérieure
Laboratory of Research of Pharmacology and Toxicology — University of Sfax (University of Sfax, Tunisie), Faculty of Sciences of Sfax (Faculty of Sciences of Sfax, Tunisie) et Hopital Universitaire Hedi Chaker (Tunisie), avec 2 autres affiliations. Pays d’affiliation : Tunisie.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.